Australasian COVID-19 Trial ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.
Trial Overview
1358 patients enrolled in trial
1358 patients randomised
42 sites activated
ASCOT randomises 1,000th patient
October 12, 2021
Australasian COVID-19 Trial (ASCOT) reached an important milestone on Tuesday, 21 September 2021, randomising the 1,000th patient into the study. T...
ASCOT removes aspirin from trial
September 10, 2021
On the 22 July 2021, the ASCOT International Trial Steering Committee (ITSC) made the decision to cease patient enrolment into aspirin-containing a...
Oxford is trialling Ivermectin - the path to this point has been rocky, why?
August 19, 2021
By Associate Professor Justin Denholm, Principal Investigator on ASCOT
The PRINCIPLE trial recently announced that their ongoing platform will now ...
The ASCOT Process
01. Identify potential treatment options
02. Evaluate candidate treatments
03. Identify effective treatments & disregard ineffective treatments
04. Generate clinical evidence that can be applied during the pandemic and within the trial itself
Use left/right arrows to navigate the slideshow or swipe left/right if using a mobile device
